Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix Infusion System
The contract sets terms for hospitals to evaluate and purchase the Ivenix Infusion System, an advanced and user-friendly infusion pump system. Vizient members represent more than $130 billion in purchases a year.
“We are thrilled to be awarded an Innovative Technology contract from Vizient for the Ivenix Infusion System,” said Christian Hauer, Executive Board Member and President of Fresenius Kabi MedTech. “The Vizient Innovative Technology process is a rigorous, clinician led review and we are proud that they concluded that the Ivenix Infusion System has the potential to advance clinical efficiency and improve patient outcomes. This validates the customer experience and feedback we have received to date. We are honored to be awarded this Vizient contract and welcome the opportunity to offer Vizient members, clinicians and patients this exciting infusion technology.”
“A product receives this type of contract when it demonstrates a unique quality that differentiates it from other products on the market,” said Kelly Flaharty, Senior Director of Contract Services for Vizient. “Our member council determined that Fresenius Kabi’s Ivenix Infusion System met this standard and recognizes its potential to improve quality outcomes.”
The Ivenix Infusion System from Fresenius Kabi includes a large-volume pump, a portfolio of administration sets and a suite of infusion management tools that seamlessly work together to inform care, advance clinical efficiency and reduce costs. The infusion platform was designed to seamlessly integrate with the hospital’s electronic medical record and other information systems.
Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to health care. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients.
Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition offering includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, its offering includes vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more.
With its corporate mission of "caring for life", Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and finds the best answers to the challenges they face.
Following its “Vision 2026”, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders.
For more information, please visit www.fresenius-kabi.com.